Brief: Grand Pharmaceutical Says Clinical Trial Application In China For Global Innovative Radionuclide-Drug Conjugate Approved
28/09/2022 11:25
Sept 28 (Reuters) - Grand Pharmaceutical Group Ltd
0512.HK :
* CLINICAL TRIAL APPLICATION IN CHINA FOR GLOBAL INNOVATIVE
RADIONUCLIDE-DRUG CONJUGATE TLX250-CDX APPROVED BY CHINA'S NMPA
Further company coverage: 0512.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grand Pharmaceutical
See all newsBrief: Grand Pharmaceutical Group Declares No Interim Dividend Has Been Paid
Grand Pharmaceutical H1 revenue rises on nuclear medicine demand
Grand Pharma rises most in over a year as drug gets US FDA fast track designation
GPN01530-2 Granted Fast Track Designation By FDA
Brief: Grand Pharmaceutical Group Enters Huadong Medicine Supply Agreement